Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR -mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer-Reference-Cited by-同舟云学术

Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR -mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer

Published:2015-09 Issue:3 Volume:89 Page:301-305
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Nishiyama Akihiro,Katakami Nobuyuki,Yoshioka Hiroshige,Iwasaku Masahiro,Korogi Yohei,Hata Akito,Takeshita Jumpei,Otsuka Kojiro,Nishino Kazumi,Uchida Junji,Okuyama Takako,Namba Yoshinobu,Mori Masahide,Fujita Shiro,Morita Satoshi

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer;Azzoli;J. Clin. Oncol.,2011

2. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Peters;Ann. Oncol.,2012

3. NCCN Practice Guidelines in Oncology; Non-Small Cell Lung Cancer-v.2;National Comprehensive Cancer Network Inc.,2013

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, open-label, phase 3 study;Zhou;Lancet Oncol.,2011

5. Erlotinib versus chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicenter, open-label, phase 3 study;Rosell;Lancet Oncol.,2012

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-eluting beads bronchial arterial chemoembolization in advanced and standard treatment-refractory/ineligible NSCLC;2024-07-23

2. Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States;Lung Cancer;2023-05

3. Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center;Meditsinskiy sovet = Medical Council;2021-08-07

4. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non–Small Cell Lung Cancer After Second-Line Treatment Failure;JAMA Network Open;2020-03-19

5. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153);Journal of Thoracic Oncology;2019-09